Braveheart Bio priced an IPO designed to fund further development of a Hengrui-derived cardiovascular therapy, pushing the program into Phase 3. The company’s listing on Nasdaq comes as a second China-origin biotech vehicle taps public markets for cash aimed at de-risking late-stage execution. The proceeds are intended to support clinical expansion and the regulatory pathway for the Hengrui asset, reflecting continued investor appetite for cross-border pipeline assets with clear Phase 3 milestones. If Phase 3 enrollment and endpoints progress as planned, the transaction highlights how “China-to-US” pipeline vehicles remain a prominent financing route for programs that have already cleared earlier development gates.